Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD

Takahashi, Hirokazu; Kessoku, Takaomi; Kawanaka, Miwa; Nonaka, Michihiro; Hyogo, Hideyuki; Fujii, Hideki; Nakajima, Tomoaki; Imajo, Kento; Tanaka, Kenichi; Kubotsu, Yoshihito; Isoda, Hiroshi; Oeda, Satoshi; Kurai, Osamu; Yoneda, Masato; Ono, Masafumi; Kitajima, Yoichiro; Tajiri, Ryo; Takamori, Ayako; Kawaguchi, Atsushi; Aishima, Shinichi; Kage, Masayoshi; Nakajima, Atsushi; Eguchi, Yuichiro; Anzai, Keizo

doi:10.1002/hep4.1696

Public

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD

Published in Hepatology Communications • Jun 17, 2021

Authors:

Hirokazu Takahashi

Takaomi Kessoku

Miwa Kawanaka

Abstract

Sodium glucose cotransporter‐2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined. We aimed to evaluate the effects of SGLT2is on the pathogenesis of NAFLD. A multicenter, randomized, controlled trial was ...

Subject

Medicine

Nonalcoholic fatty liver disease

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!